Imatinib for Multiple Sclerosis (MS) Relapses

• Status: Recruiting
• Trial end date: 2023-07-30

Summary

To investigate if treatment with Imatinib results in a better outcome than standard care in form of Methylprednisolone(MP) after MS-associated relapses.

• Phase: Phase 2

Details

• Lead Sponsor: Tomas Olsson
• Collaborator: The Swedish Research Council
• Treatments: Imatinib Mesylate; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate